A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Inclusion Criteria

• •Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study.
• •Male or female ≥ 8 years old.
• •Subject has a clinical diagnosis of common warts.
• •Subject chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value/s as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization.
• •Women of childbearing potential (WOCBP) must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study.
• •Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any Target and Non-Target Warts or which exposes the subject to an unacceptable risk by study participation.
• •Subject is willing and able to follow all study instructions and to attend all study visits.